T

he pharmaceutical industry trade group hopes to convince you that it is not all bark and no bite.

In response to the outcry over Marathon Pharmaceuticals, which plans to sell a decades-old drug for $89,000 and also maintain a monopoly, the Pharmaceutical Research and Manufacturers of America slammed the company for “actions [that] are not consistent with the mission of our organization.” And the group promised a “comprehensive review” of its membership criteria.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.